share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股sec公告 ·  05/06 21:33
牛牛AI助理已提取核心訊息
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, has announced that it has exceeded the Nasdaq's minimum stockholders' equity requirement of $2.5 million, as per Nasdaq Listing Rule 5550(b)(1). The company reported on May 6, 2024, that its stockholders' equity is significantly above the threshold, indicating regained compliance with the equity rule. Allarity is now awaiting formal confirmation from Nasdaq regarding its compliance status. Concurrently, Allarity has decided to withdraw its Registration Statement on Form S-1, initially filed with the SEC on October 30, 2023. This move comes after a reassessment of the company's financial position and recent improvements in equity status. CEO Thomas Jensen expressed confidence in the company's regulatory alignment and its focus on advancing stenoparib, a therapy for advanced ovarian cancer, using its proprietary Drug Response Predictor (DRP®) companion diagnostic. The company plans to disclose the updated equity amount in its upcoming Form 10-Q, expected to be filed on May 14, 2024, which will provide detailed financial insights to stockholders.
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, has announced that it has exceeded the Nasdaq's minimum stockholders' equity requirement of $2.5 million, as per Nasdaq Listing Rule 5550(b)(1). The company reported on May 6, 2024, that its stockholders' equity is significantly above the threshold, indicating regained compliance with the equity rule. Allarity is now awaiting formal confirmation from Nasdaq regarding its compliance status. Concurrently, Allarity has decided to withdraw its Registration Statement on Form S-1, initially filed with the SEC on October 30, 2023. This move comes after a reassessment of the company's financial position and recent improvements in equity status. CEO Thomas Jensen expressed confidence in the company's regulatory alignment and its focus on advancing stenoparib, a therapy for advanced ovarian cancer, using its proprietary Drug Response Predictor (DRP®) companion diagnostic. The company plans to disclose the updated equity amount in its upcoming Form 10-Q, expected to be filed on May 14, 2024, which will provide detailed financial insights to stockholders.
臨床階段的生物製藥公司Allarity Therapeutics, Inc.(納斯達克股票代碼:ALLR)宣佈,根據納斯達克上市規則5550(b)(1),它已超過納斯達克規定的250萬美元的最低股東權益要求。該公司於2024年5月6日報告稱,其股東權益大大高於門檻,這表明已恢復遵守股權規則。Allarity目前正在等待納斯達克對其合規狀況的正式確認。同時,Alarity已決定撤回其最初於2023年10月30日向美國證券交易委員會提交的S-1表格註冊聲明。此舉是在重新評估了公司的財務狀況以及最近股權狀況的改善之後採取的。首席執行官托馬斯·詹森對公司的監管協調以及專注於使用其專有的藥物反應預測器(DRP®)伴隨診斷來推進晚期卵巢癌治療的stenoparib表示了信心。該公司計劃在即將發佈的10-Q表格中披露最新的股本金額,該表格預計將於2024年5月14日提交,這將爲股東提供詳細的財務見解。
臨床階段的生物製藥公司Allarity Therapeutics, Inc.(納斯達克股票代碼:ALLR)宣佈,根據納斯達克上市規則5550(b)(1),它已超過納斯達克規定的250萬美元的最低股東權益要求。該公司於2024年5月6日報告稱,其股東權益大大高於門檻,這表明已恢復遵守股權規則。Allarity目前正在等待納斯達克對其合規狀況的正式確認。同時,Alarity已決定撤回其最初於2023年10月30日向美國證券交易委員會提交的S-1表格註冊聲明。此舉是在重新評估了公司的財務狀況以及最近股權狀況的改善之後採取的。首席執行官托馬斯·詹森對公司的監管協調以及專注於使用其專有的藥物反應預測器(DRP®)伴隨診斷來推進晚期卵巢癌治療的stenoparib表示了信心。該公司計劃在即將發佈的10-Q表格中披露最新的股本金額,該表格預計將於2024年5月14日提交,這將爲股東提供詳細的財務見解。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。